A collaborative research study has discovered the effective use of magnetic resonance spectroscopy in the noninvasive diagnosis and molecular characterization of brain tumors in children.
A collaborative research study has discovered the effective use of magnetic resonance spectroscopy (MRS) in the noninvasive diagnosis and molecular characterization of brain tumors in children. This tool has the potential for early intervention and precision therapy.
MRS can adequately characterize tumor without the need for a biopsy. The authors of this study published in Neuro-Oncology evaluated the hypothesis that MRS-based metabolite concentrations could be used to differentiate between the molecular subgroups of medulloblastoma (SHH, Groups 3/4, WNT). Levels of 14 metabolites were measured in frozen tissue samples of 30 patients. Group 3 and 4 tumors had metabolic profiles with detectable taurine, low levels of lipids, and high levels of creatinine. SHH tumors had prominent choline and lipid with low levels of creatinine and minimal or no taurine.
Based on these results, the authors developed a classification system of 5 metabolites to discriminate between Group 3/4 and SHH medulloblastomas. This technique, if validated, could allow for earlier intervention without having to wait for surgery and analysis of the tumor tissue, which is the current norm. Earlier subgroup determination could significantly improve outcomes by permitting the use of precision therapy.
“MR spectroscopy is widely available, noninvasive and provides information on cellular metabolism, which is different in healthy and diseased tissue,” said Stefan Bluml, PhD, investigator at The Saban Research Institute of Children’s Hospital Los Angeles and first author of the study in an interview.
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More